The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1183
May 24, 2004
View Complete Issue         Table of Contents 2019 
Imiquimod (Aldara) for Actinic Keratoses
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Imiquimod (Aldara) for Actinic Keratoses
May 24, 2004 (Issue: 1183)
Imiquimod cream 5% (Aldara - 3M), an immune modifier previously approved for treatment of genital and perianal warts (Medical Letter 1997; 39:118), has now been approved by the FDA for treatment of actinic keratoses (AKs) on the face or scalp, and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Imiquimod (Aldara) for Actinic Keratoses
Article code: 1183b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.